Literature DB >> 10720580

CYP11B2 gene polymorphisms in idiopathic hyperaldosteronism.

P Mulatero1, D Schiavone, F Fallo, F Rabbia, C Pilon, L Chiandussi, L Pascoe, F Veglio.   

Abstract

Primary aldosteronism is characterized by autonomous production of aldosterone and arterial hypertension, and it occurs in 2 principal forms: aldosterone-producing adenoma (APA) and idiopathic hyperaldosteronism (IHA). APA can be cured through removal of the adenoma, whereas IHA leads to hypertension that must be treated with medication. The origin of the autonomous aldosterone production in IHA is poorly understood, but genetic factors may contribute to its cause. To test the hypothesis that variants of the aldosterone synthase gene may contribute to susceptibility to IHA, we compared genotypes at 3 polymorphic sites in the CYP11B2 gene in patients with IHA (n=90) with those found in patients with APA (n=38), in patients with essential hypertension (n=72), and in normotensive individuals (n=102). We observed significant linkage disequilibrium among the 3 polymorphisms with 2 frequent haplotypes in all groups studied. One haplotype (C2R) was found to be increased in frequency in the IHA group (47%) compared with the other groups, which had a similar haplotype frequency (36%). The 3 polymorphisms studied have been implicated in either essential hypertension or excess aldosterone production in previous studies. Because of the strong linkage disequilibrium, the observed results could be due to the action of any 1 of the 3 alleles or to another allele in linkage disequilibrium with them. Our results suggest that variations in the CYP11B2 gene may contribute to dysregulation of aldosterone synthesis and lead to susceptibility to IHA.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10720580     DOI: 10.1161/01.hyp.35.3.694

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  7 in total

Review 1.  Hypertension and the expanding role of aldosterone.

Authors:  Scott M Mackenzie; John Connell
Journal:  Curr Hypertens Rep       Date:  2006-06       Impact factor: 5.369

Review 2.  Aldosterone and arterial hypertension.

Authors:  Andreas Tomaschitz; Stefan Pilz; Eberhard Ritz; Barbara Obermayer-Pietsch; Thomas R Pieber
Journal:  Nat Rev Endocrinol       Date:  2009-12-22       Impact factor: 43.330

3.  18-oxocortisol measurement in adrenal vein sampling as a biomarker for subclassifying primary aldosteronism.

Authors:  Yasuhiro Nakamura; Fumitoshi Satoh; Ryo Morimoto; Masataka Kudo; Kei Takase; Celso E Gomez-Sanchez; Seijiro Honma; Mitsunobu Okuyama; Kouwa Yamashita; William E Rainey; Hironobu Sasano; Sadayoshi Ito
Journal:  J Clin Endocrinol Metab       Date:  2011-05-18       Impact factor: 5.958

Review 4.  Understanding primary aldosteronism: impact of next generation sequencing and expression profiling.

Authors:  Silvia Monticone; Tobias Else; Paolo Mulatero; Tracy A Williams; William E Rainey
Journal:  Mol Cell Endocrinol       Date:  2014-09-18       Impact factor: 4.102

5.  ARMC5 mutation analysis in patients with primary aldosteronism and bilateral adrenal lesions.

Authors:  P Mulatero; F Schiavi; T A Williams; S Monticone; G Barbon; G Opocher; F Fallo
Journal:  J Hum Hypertens       Date:  2015-10-08       Impact factor: 3.012

6.  Salt-dependent Blood Pressure in Human Aldosterone Synthase-Transgenic Mice.

Authors:  Huiying Gu; Zhizhong Ma; Jian Wang; Timothy Zhu; Nicole Du; Adam Shatara; Xin Yi; Mark C Kowala; Yansheng Du
Journal:  Sci Rep       Date:  2017-03-28       Impact factor: 4.379

7.  Correlation between CYP11B2 polymorphism and the risk of preeclampsia.

Authors:  Yan Wang; Minhua Zhou; Xun Deng; Yanjiao Ma; Deqi Jiang
Journal:  Medicine (Baltimore)       Date:  2020-11-25       Impact factor: 1.889

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.